JP2007512347A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007512347A5 JP2007512347A5 JP2006541438A JP2006541438A JP2007512347A5 JP 2007512347 A5 JP2007512347 A5 JP 2007512347A5 JP 2006541438 A JP2006541438 A JP 2006541438A JP 2006541438 A JP2006541438 A JP 2006541438A JP 2007512347 A5 JP2007512347 A5 JP 2007512347A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- compound
- hmg
- composition according
- coa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 14
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 claims 7
- 239000000556 agonist Substances 0.000 claims 7
- FJLGEFLZQAZZCD-JUFISIKESA-N (3S,5R)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-JUFISIKESA-N 0.000 claims 6
- KJTLQQUUPVSXIM-ZCFIWIBFSA-N (R)-mevalonic acid Chemical compound OCC[C@](O)(C)CC(O)=O KJTLQQUUPVSXIM-ZCFIWIBFSA-N 0.000 claims 6
- KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 claims 6
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 6
- 238000006243 chemical reaction Methods 0.000 claims 6
- 208000010412 Glaucoma Diseases 0.000 claims 5
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 4
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 4
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 claims 4
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 claims 4
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims 4
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 4
- 229960005370 atorvastatin Drugs 0.000 claims 4
- 229960005110 cerivastatin Drugs 0.000 claims 4
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 claims 4
- 229960003765 fluvastatin Drugs 0.000 claims 4
- 229960004844 lovastatin Drugs 0.000 claims 4
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 4
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims 4
- 229940002612 prodrug Drugs 0.000 claims 4
- 239000000651 prodrug Substances 0.000 claims 4
- 229960002855 simvastatin Drugs 0.000 claims 4
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 4
- 239000000150 Sympathomimetic Substances 0.000 claims 3
- 239000002876 beta blocker Substances 0.000 claims 3
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 230000005764 inhibitory process Effects 0.000 claims 3
- 230000003547 miosis Effects 0.000 claims 3
- 230000001975 sympathomimetic effect Effects 0.000 claims 3
- VDSBXXDKCUBMQC-HNGSOEQISA-N (4r,6s)-6-[(e)-2-[2-(4-fluoro-3-methylphenyl)-4,4,6,6-tetramethylcyclohexen-1-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C1=C(F)C(C)=CC(C=2CC(C)(C)CC(C)(C)C=2\C=C\[C@H]2OC(=O)C[C@H](O)C2)=C1 VDSBXXDKCUBMQC-HNGSOEQISA-N 0.000 claims 2
- 229940122072 Carbonic anhydrase inhibitor Drugs 0.000 claims 2
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims 2
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 claims 2
- 229950003040 dalvastatin Drugs 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229950009116 mevastatin Drugs 0.000 claims 2
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 claims 2
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 claims 2
- 229960002965 pravastatin Drugs 0.000 claims 2
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 2
- 239000002522 prostaglandin receptor stimulating agent Substances 0.000 claims 2
- 239000000018 receptor agonist Substances 0.000 claims 2
- 229940044601 receptor agonist Drugs 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- -1 verostatin Chemical compound 0.000 claims 2
- 102000004316 Oxidoreductases Human genes 0.000 claims 1
- 108090000854 Oxidoreductases Proteins 0.000 claims 1
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 claims 1
- 239000003889 eye drop Substances 0.000 claims 1
- 229940012356 eye drops Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 150000003180 prostaglandins Chemical class 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52491203P | 2003-11-26 | 2003-11-26 | |
| PCT/US2004/039657 WO2005053683A1 (en) | 2003-11-26 | 2004-11-26 | A method of preventing or treating glaucoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007512347A JP2007512347A (ja) | 2007-05-17 |
| JP2007512347A5 true JP2007512347A5 (https=) | 2008-01-17 |
Family
ID=34652282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006541438A Pending JP2007512347A (ja) | 2003-11-26 | 2004-11-26 | 緑内障を予防するかまたは治療する方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US8415364B2 (https=) |
| EP (1) | EP1722780A4 (https=) |
| JP (1) | JP2007512347A (https=) |
| WO (1) | WO2005053683A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE281432T1 (de) | 1999-03-05 | 2004-11-15 | Univ Duke | C-16 ungesätigte fp-selektive prostaglandin analoge |
| US20020172693A1 (en) | 2000-03-31 | 2002-11-21 | Delong Michell Anthony | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
| US20020037914A1 (en) | 2000-03-31 | 2002-03-28 | Delong Mitchell Anthony | Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins |
| US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
| ATE404189T1 (de) * | 2004-04-26 | 2008-08-15 | Alcon Inc | Statine zur behandlung von okularer hypertonie und glaukom |
| EP1812017A2 (en) * | 2004-10-21 | 2007-08-01 | Duke University | Ophthamological drugs |
| US20070254920A1 (en) * | 2006-04-26 | 2007-11-01 | Aerie Pharmaceuticals, Inc. | Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use |
| US9597289B2 (en) | 2006-04-26 | 2017-03-21 | Rosemont Pharmaceuticals Ltd. | Liquid oral simvastatin compositions |
| US20090202524A1 (en) * | 2007-10-31 | 2009-08-13 | Alcon Research, Ltd. | Pai-1 expression and activity inhibitors for the treatment of ocular disorders |
| US8623918B2 (en) * | 2008-10-29 | 2014-01-07 | Novaer Holdings, Inc. | Amino acid salts of prostaglandins |
| US8722739B2 (en) | 2008-10-29 | 2014-05-13 | Novaer Holdings, Inc. | Amino acid salts of prostaglandins |
| US12478503B2 (en) | 2009-05-18 | 2025-11-25 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| US10493274B2 (en) | 2013-12-09 | 2019-12-03 | Purdue Research Foundation | Optical pressure treatment through electrical stimulation |
| AU2018312121B2 (en) | 2017-08-04 | 2023-12-21 | Purdue Research Foundation | Multi-coil wireless power transfer assembly for wireless glaucoma therapy |
| US11191962B2 (en) | 2018-03-12 | 2021-12-07 | Purdue Research Foundation | Stimulus coil and pulse generator for wireless glaucoma therapy |
| KR20230012539A (ko) | 2020-05-13 | 2023-01-26 | 디스크 메디슨, 인크. | 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체 |
| WO2025080770A1 (en) * | 2023-10-10 | 2025-04-17 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Ocular applications of combination therapy using statins and matrix bound vesicles (mbvs) |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5612114B2 (https=) * | 1974-06-07 | 1981-03-18 | ||
| US4231938A (en) * | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
| US4444784A (en) * | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
| DK149080C (da) * | 1980-06-06 | 1986-07-28 | Sankyo Co | Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre |
| US4450171A (en) * | 1980-08-05 | 1984-05-22 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
| US4739073A (en) * | 1983-11-04 | 1988-04-19 | Sandoz Pharmaceuticals Corp. | Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof |
| US5354772A (en) * | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
| US4681893A (en) * | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
| JP2569746B2 (ja) * | 1987-08-20 | 1997-01-08 | 日産化学工業株式会社 | キノリン系メバロノラクトン類 |
| US5041450A (en) * | 1988-06-29 | 1991-08-20 | Research Corporation Technologies, Inc. | Treatment of ocular inflammation |
| JP2853227B2 (ja) | 1988-10-13 | 1999-02-03 | ノバルテイス・アクチエンゲゼルシヤフト | ７置換‐ヘプト‐６‐エン酸、ヘプタン酸及び誘導体並びにそれらの中間体の製法 |
| FR2647675B1 (fr) * | 1989-06-05 | 1994-05-20 | Sanofi | Utilisation d'un derive de la statine dans le traitement des affections oculaires |
| FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| US5683867A (en) * | 1990-06-11 | 1997-11-04 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: blended SELEX |
| US5177080A (en) | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
| JP3528186B2 (ja) * | 1991-06-24 | 2004-05-17 | 日産化学工業株式会社 | 光学活性キノリンメバロン酸のジアステレオマー塩 |
| ATE179074T1 (de) * | 1991-11-07 | 1999-05-15 | Univ Southern California | Zusammensetzungen und verfahren zur verhinderung der adhäsionbildung |
| HU9203780D0 (en) * | 1991-12-12 | 1993-03-29 | Sandoz Ag | Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them |
| US5536814A (en) * | 1993-09-27 | 1996-07-16 | La Jolla Cancer Research Foundation | Integrin-binding peptides |
| JP2800877B2 (ja) | 1993-12-28 | 1998-09-21 | 伊藤ハム株式会社 | 血中トリグリセリド濃度上昇抑制ペプチド及び当該ペプチドを有効成分として含む血中トリグリセリド濃度上昇抑制剤 |
| US5753230A (en) * | 1994-03-18 | 1998-05-19 | The Scripps Research Institute | Methods and compositions useful for inhibition of angiogenesis |
| EP0738510A3 (fr) * | 1995-04-20 | 2005-12-21 | L'oreal | Utilisation d'un inhibiteur d'HMG-coenzyme A-reductase pour lutter contre le vieillissement de la peau et pour traiter l'acné. Composition comprenant au moins un inhibiteur HMG-coenzyme A reductase et au moins un actif possédant des propriétes desquamantes |
| US5811515A (en) * | 1995-06-12 | 1998-09-22 | California Institute Of Technology | Synthesis of conformationally restricted amino acids, peptides, and peptidomimetics by catalytic ring closing metathesis |
| ATE308981T1 (de) | 1995-08-14 | 2005-11-15 | Scripps Research Inst | Verfahren und mittel zur hemmung der durch alpha v beta 5 vermittelten angiogenese |
| JPH1017488A (ja) | 1996-06-25 | 1998-01-20 | Asahi Glass Co Ltd | 緑内障治療薬 |
| US5900414A (en) * | 1996-08-29 | 1999-05-04 | Merck & Co., Inc. | Methods for administering integrin receptor antagonists |
| CA2307285C (en) | 1998-08-17 | 2009-03-31 | Senju Pharmaceutical Co., Ltd. | Agent for prophylaxis and treatment of glaucoma |
| JP2000336042A (ja) * | 1999-03-25 | 2000-12-05 | Santen Pharmaceut Co Ltd | 眼圧下降剤 |
| US20030018061A1 (en) * | 2000-01-28 | 2003-01-23 | Kohei Ogawa | Novel remedies with the use of beta 3 agonist |
| SE0002354D0 (sv) | 2000-06-22 | 2000-06-22 | Astrazeneca Ab | New formulation |
| NZ527408A (en) | 2001-02-22 | 2005-04-29 | Skyepharma Canada Inc | Hydroxymethylglutarylcoenzyme A (HMG CoA) reductase inhibitor (or a statin) and a fibrate in a single effective oral dosage form to treat dyslipidaemia and dyslipoproteinaemia |
| EP1298223A3 (en) * | 2001-09-28 | 2003-07-23 | Pfizer Products Inc. | Methods related to the A-C repeat Z-sequence upstream from the aldose reductase gene |
| SE0104334D0 (sv) * | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| JP4300347B2 (ja) * | 2002-01-29 | 2009-07-22 | 参天製薬株式会社 | ブナゾシンとプロスタグランジン類からなる緑内障治療剤 |
| CA2478653A1 (en) * | 2002-03-18 | 2003-09-25 | Pfizer Products Inc. | Methods of treatment with selective ep4 receptor agonists |
| TW200810743A (en) * | 2002-03-22 | 2008-03-01 | Novartis Ag | Combination of organic compounds |
| US20030195167A1 (en) | 2002-04-15 | 2003-10-16 | Kowa Co., Ltd. | PTX3-gene expression inhibitor |
| JP2004149480A (ja) | 2002-10-31 | 2004-05-27 | Saisentan Igaku Kenkyusho:Kk | 経口又は経皮投与用の眼科疾患治療剤 |
| US20040248972A1 (en) * | 2003-05-16 | 2004-12-09 | Ambit Biosciences Corporation | Compounds and uses thereof |
| ATE404189T1 (de) * | 2004-04-26 | 2008-08-15 | Alcon Inc | Statine zur behandlung von okularer hypertonie und glaukom |
| WO2005105155A1 (en) | 2004-04-28 | 2005-11-10 | Saitama Medical School | Methods for delivering a gene product to the eye |
-
2004
- 2004-11-26 JP JP2006541438A patent/JP2007512347A/ja active Pending
- 2004-11-26 WO PCT/US2004/039657 patent/WO2005053683A1/en not_active Ceased
- 2004-11-26 US US10/580,477 patent/US8415364B2/en not_active Expired - Fee Related
- 2004-11-26 EP EP04812221A patent/EP1722780A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007512347A5 (https=) | ||
| Corsini et al. | New insights into the pharmacodynamic and pharmacokinetic properties of statins | |
| RU2007126483A (ru) | Гетероциклические ингибиторы аспартилпротеазы | |
| CA2536187C (en) | Pharmaceutical composition comprising a combination of metformin and a statin | |
| JP2002501887A5 (ja) | アルツハイマー病の治療用の薬剤の製造のための血漿トリグリセライドレベル低下剤の使用 | |
| WO2001068096A2 (en) | Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders | |
| US20150272944A1 (en) | Novel triglyceride reducing agent | |
| EP2131832A2 (en) | Combination therapy, composition and methods for the treatment of cardiovascular disorders | |
| JP2002508320A5 (https=) | ||
| AU2005237543B2 (en) | Statins for the treatment of ocular hypertension and glaucoma | |
| JP2005200419A5 (https=) | ||
| RU2007149337A (ru) | Новый способ лечения гиперлипидемии | |
| JP2003524582A5 (https=) | ||
| WO2005058310A3 (en) | Use of stating for the treatment of metabolic syndrome | |
| JP2002506818A5 (https=) | ||
| JP2008513379A5 (https=) | ||
| RU2006114579A (ru) | Комбинации ингибитора биосинтеза холестерина и растворимого волокна для лечения состояний, связанных с повышенным содержанием холестерина | |
| RU2007148908A (ru) | Составы для снижения риска возникновения вызванной лекарственными средствами аритмии | |
| CA2798707A1 (en) | Association of xanthine oxidase inhibitors and statins and use thereof | |
| CN1473042A (zh) | 药物组合物 | |
| US20050182106A1 (en) | Medicinal composition for mitigating blood lipid or lowering blood homocysteine | |
| EP1358879A1 (en) | Antilipemic agents | |
| RU2380360C2 (ru) | Дифенилазетидиноновые производные, обладающие активностью, ингибирующей всасывание холестерина | |
| HK1111632B (en) | Novel triglyceride reducing agent | |
| CO5611117A2 (es) | Combinacion de compuestos organicos |